Target intelligence / Profile preview

Tumor necrosis factor ligand superfamily member 13 (APRIL) (APRIL)

Target
APRIL
Molecular classification
Other, Cytokine
01

Overview

Tumor necrosis factor ligand superfamily member 13 (TNFSF13), commonly known as A proliferation-inducing ligand (APRIL), is a cytokine belonging to the tumor necrosis factor (TNF) superfamily. It is primarily expressed by myeloid cells, such as macrophages and dendritic cells, and undergoes proteolytic cleavage by furin to release a biologically active soluble homotrimer. APRIL plays a critical role in humoral immunity by binding to two key receptors: transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA). This interaction triggers downstream signaling pathways, such as NF-κB, which are essential for B-cell survival, plasma cell maintenance, and immunoglobulin class switching (particularly to IgA).

Dysregulation and overexpression of APRIL are heavily implicated in the pathogenesis of autoimmune diseases, most notably IgA nephropathy (IgAN), where it drives the overproduction of galactose-deficient IgA1 (Gd-IgA1). It is also associated with systemic lupus erythematosus (SLE), rheumatoid arthritis, and B-cell malignancies like multiple myeloma. Consequently, APRIL has emerged as a major therapeutic target. Biologics targeting this pathway include selective monoclonal antibodies like sibeprenlimab and zigakibart, as well as dual APRIL/BAFF inhibitors like atacicept, telitacicept, and povetacicept. These therapies aim to reduce pathogenic antibody production, alleviate proteinuria, and preserve kidney function, though they carry risks of infection and hypogammaglobulinemia due to systemic B-cell suppression.

Other names
A proliferation-inducing ligandTNFSF13CD256TALL-2TRDL-1ZTNF2TNF- and APOL-related leukocyte expressed ligand 2TNF-related death ligand 1
02

Mechanism of action

Inhibition of APRIL (TNFSF13) binding to its receptors TACI (TNFRSF13B) and BCMA (TNFRSF17), thereby preventing downstream signaling pathways (such as NF-κB) that promote B-cell survival, plasma cell maintenance, and immunoglobulin class switching.

03

Biological functions

Immune responseB cell activationB cell proliferationPlasma cell survivalImmunoglobulin class switchingAntibody productionApoptosisSignal transduction
04

Disease associations

Autoimmune diseaseIgA nephropathyCancerMultiple myelomaSystemic lupus erythematosusRheumatoid arthritisSjögren's syndrome
05

Safety considerations

Increased risk of infections (particularly upper respiratory tract infections)Hypogammaglobulinemia (reduction in total IgG, IgA, and IgM levels)Impaired vaccine response (live vaccines are contraindicated during treatment)Potential for neutropenia or other cytopenias
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Serum Gd-IgA1 levelsSerum IgA levelsSerum IgG levelsSerum IgM levelsProteinuria (Urine protein-to-creatinine ratio / UPCR)Estimated glomerular filtration rate (eGFR)Hematuria resolution

Beyond the preview

Go deeper on Tumor necrosis factor ligand superfamily member 13 (APRIL) (APRIL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor ligand superfamily member 13 (APRIL) (APRIL).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call